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Abstract 
Cocaine users consistently display cognitive impairments. However, it is still unknown whether these 
impairments are cocaine-induced and if they are reversible. Therefore, we examined the relation 
between changing intensity of cocaine use and the development of cognitive functioning within one 
year. The present data were collected as part of the longitudinal Zurich Cocaine Cognition Study 
(ZuCo2St). Forty-eight psychostimulant-naïve controls and 57 cocaine users (19 with increased, 19 
with decreased, and 19 with unchanged cocaine use) were eligible for analysis. At baseline and after a 
one-year follow-up, cognitive performance was measured by a global cognitive index and four 
neuropsychological domains (attention, working memory, declarative memory, executive functions), 
calculated from 13 parameters of a broad neuropsychological test battery. Intensity of cocaine use was 
objectively determined by quantitative six-month hair toxicology at both test sessions. Substantially 
increased cocaine use within one year (mean +297%) was associated with reduced cognitive 
performance primarily in working memory. By contrast, decreased cocaine use (-72%) was linked to 
small cognitive improvements in all four domains. Importantly, users who ceased taking cocaine 
seemed to recover completely, attaining a cognitive performance level similar to that of the control 
group. However, cognitive recovery was correlated with age of onset of cocaine use – early onset 
users showed hampered recovery. These longitudinal data suggest that cognitive impairment might be 
partially cocaine-induced but also reversible within one year, at least after moderate exposure. The 
reversibility indicates that neuroplastic adaptations underlie cognitive changes in cocaine users, which 
are potentially modifiable in psychotherapeutical or pharmacological interventions.  
 
Keywords: Reversibility, stimulants, brain maturation, neuropsychology, cognition, cocaine 
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Introduction 
The annual number of cocaine users is currently estimated at 17 million people worldwide (United 
Nations Office on Drugs and Crime, 2013). Because of its high addictive potential and harmful effects 
on mental and physical well-being (Degenhardt and Hall, 2012; Nutt et al, 2007), the use of cocaine is 
a major public health issue with substantial societal and economic costs (Degenhardt et al, 2012).  
Accumulating evidence suggests that dependent (Goldstein et al, 2004; Jovanovski et al, 2005; 
Vonmoos et al, 2013; Woicik et al, 2009) and also recreational (Colzato et al, 2009; Reske et al, 2010; 
Soar et al, 2012; Vonmoos et al, 2013) cocaine use is associated with broad neuropsychological 
impairment. Remarkably, a first study indicates that 30% of dependent users, and even 12% of 
recreational users exhibit clinically relevant global cognitive impairment (Vonmoos et al, 2013). 
Studies have shown deficits in attention, working memory, and declarative memory in chronic cocaine 
users, whereas the heterogeneous concept of executive functions has yielded mixed results 
(Jovanovski et al, 2005; Vonmoos et al, 2013). We recently demonstrated that cocaine users 
additionally display inferior social cognition, including prosodic and cross-modal emotion recognition, 
emotional empathy, mental perspective-taking, and social decision-making (Hulka et al, 2014; Hulka 
et al, 2013; Preller et al, 2013). A worse social cognitive performance was correlated with a smaller 
social network and more criminal offenses in cocaine users (Preller et al, 2013), pointing to the 
importance of cognitive health for social and occupational functioning in drug users as in psychiatric 
patients (Lee et al, 2013). Moreover, neuropsychological performance predicts the attainment of 
treatment objectives and the likelihood of treatment dropout in substance users (Teichner et al, 2002). 
Today, it is still unclear whether these cognitive impairments are cocaine-induced and if they are 
reversible. Studies on chronic cocaine self-administration in rhesus monkeys suggest that some 
alterations in attention, learning, and working memory might be cocaine-induced (Gould et al, 2012; 
Liu et al, 2008; Porter et al, 2011). In contrast to these animal studies, research with human cocaine 
users has focused on the effects of drug abstinence on cognition. The few and preliminary cross-
sectional (Bolla et al, 1999; De Oliveira et al, 2009) and longitudinal (Bauer, 1996; Bolla et al, 2000; 
Di Sclafani et al, 2002; van Gorp et al, 1999) studies either indicate persisting neuropsychological 
impairment in attention (Bauer, 1996), declarative memory (van Gorp et al, 1999), and executive 
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function (De Oliveira et al, 2009), or suggest some recovery effects in working memory (Di Sclafani 
et al, 2002) and verbal declarative memory (De Oliveira et al, 2009). However, it should be noted that 
even longitudinal studies in humans cannot prove causal relationships between drug intake and 
cognition. Furthermore, cocaine use was self-reported and solely controlled with drug urine tests but 
not hair toxicology analyses, which would have enabled a reliable detection of drug use during the last 
months. Finally, these studies had relatively brief follow-up intervals with strongly varying abstinence 
durations (one week to six months) and several studies reported only minimal information on the 
severity of drug use. Notably, no longitudinal study has investigated the association between 
escalating cocaine use and cognitive impairment yet. 
Accordingly, we aimed to overcome these limitations of previous studies by means of a longitudinal 
study specifically investigating the linkage between changing cocaine use and cognitive performance 
during a one-year interval. Therefore, we categorized cocaine users in the Zurich Cocaine Cognition 
Study (ZuCo2St) as decreasers, stable users, or increasers after the one-year follow-up. We then 
compared the course of cognitive performance between decreasers and increasers, whose test scores 
were normalized to the test-retest effects of a psychostimulant-naïve control group that was also 
assessed twice. Because we were interested in the specific effects of cocaine, relatively pure users with 
little co-use of other illegal drugs were initially recruited. To objectively assess the initial severity and 
change in cocaine use and to control for co-use of other drugs, we performed quantitative hair and 
urine toxicology analyses at baseline and follow-up. Because we recently reported strong dose-
response correlations between several cocaine use parameters and cognitive performance in cocaine 
users from the cross-sectional part of this study (Vonmoos et al, 2013), and based on previous animal 
studies suggesting that cognitive impairment in cocaine users might be drug-induced (Gould et al, 
2012; Liu et al, 2008; Porter et al, 2011), we hypothesized that escalating cocaine use is associated 
with further cognitive impairment. Based on data suggesting that long-term cocaine abstinence of 
cocaine might be associated with partial recovery of neuropsychological performance (De Oliveira et 
al, 2009; Di Sclafani et al, 2002; van Gorp et al, 1999), we expect to find improved cognition in 
cocaine users with considerably decreased or ceased cocaine consumption.  
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Materials and Methods 
Participants  
From a cross-sectional sample of 234 participants, 48 psychostimulant-naïve controls and 57 cocaine 
users could be included in the longitudinal study (recruitment and selection details Methods S1). At 
baseline, general exclusion criteria were neurological disorders or head injuries, severe somatic 
diseases, and any medication affecting the central nervous system. Controls were also excluded if they 
displayed current or previous DSM-IV Axis I psychiatric disorders (except for nicotine addiction), and 
regular illegal drug use (>15 occasions lifetime, except for recreational cannabis use). Exclusion 
criteria for cocaine users were use of opioids, a polytoxic drug use pattern according to DSM-IV, and 
DSM-IV Axis I adult psychiatric disorders – except for cocaine, cannabis, nicotine, and alcohol 
abuse/dependence; history of affective disorders (current major depression was excluded); and 
attention deficit hyperactivity disorder (ADHD). Inclusion criteria for cocaine users were cocaine use 
of >0.5g per month, cocaine as primary drug, and an abstinence duration of <six months at baseline.  
Participants were asked to abstain from illegal substances for at least 72h and from alcohol for 24h 
before test sessions. Compliance with these instructions was controlled using urine screenings (semi-
quantitative enzyme multiplied immunoassay method; for technical details see Vonmoos et al, 2013). 
Drug use severity was assessed by six-month hair toxicology analyses (liquid chromatography-tandem 
mass spectrometry; Vonmoos et al, 2013). The study was approved by the Cantonal Ethics Committee 
of Zurich. All participants provided written informed consent and received compensation for their 
participation.  
 
Group assignment  
The decisive criterion for replicable group assignment was a combination of absolute and relative 
changes in cocaine concentration in hair samples between baseline (t1) and follow-up (t2). The 
absolute criterion was based on a shift in cocaine concentration of at least ±0.5 ng/mg, according to a 
commonly accepted cut-off value for reliably detection of cocaine use (Bush, 2008; Cooper et al, 
2012). The relative criterion was based on a minimal increase of 20% or a minimal decrease of 10% in 
the robust hair toxicology parameter cocainetotal (=cocaine+benzoylecgonine+norcocaine)(Hoelzle et 
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al, 2008). According to these criteria, cocaine users were divided into three groups of similar size: 19 
cocaine increasers consumed substantially more cocaine at follow-up (mean increase +30.4 ng/mg 
[+297%], range +0.5 to +268.5 ng/mg [+20% to +5374%], SD 61.9 ng/mg), whereas 19 cocaine 
decreasers consumed substantially less cocaine (mean decrease -10.6 ng/mg [-72%], range -116.9 to -
0.6 ng/mg [-100% to -12%], SD 26.7 ng/mg), and 19 users with a relatively stable cocaine use pattern 
did not meet both criteria, and, thus, were not further analyzed (Figure S1). 
 
Procedure 
The test procedure was similar in baseline and follow-up. Trained psychologists conducted the 
Structured Clinical Interview for DSM-IV (SCID-I)(American Psychiatric Association, 1994). Drug 
use was assessed with a structured and standardized Interview for Psychotropic Drug Consumption 
(Quednow et al, 2004). Cognitive performance was assessed with a neuropsychological test battery 
comprising three tasks of the Cambridge Neuropsychological Test Automated Battery (CANTAB, 
www.cantab.com): Rapid Visual Processing (RVP), Spatial Working Memory (SWM), Paired 
Associates Learning (PAL); a German version of the Rey Auditory Verbal Learning Test 
(RAVLT)(Helmstaedter et al, 2001); and the Letter Number Sequencing Task (LNST)(Wechsler, 
1997). At follow-up, parallel test-versions were used for the PAL, RAVLT, and LNST. In contrast to 
the cross-sectional analysis, we excluded the CANTAB Intra/Extradimensional Set Shifting (IED) 
from the longitudinal analysis because of an evident ceiling effect at baseline (Vonmoos et al, 2013). 
Analogous to the cross-sectional part of the study (Vonmoos et al, 2013), 13 predefined main 
cognitive test parameters were z-transformed on the basis of means and standard deviations of the 
control group (n=48) at baseline. If necessary, test scores were reversed so that high scores always 
indicated better cognitive performance. Test parameters were reduced to four cognitive domains 
(attention, working memory, declarative memory, and executive functions, for details see Methods 
S2). Furthermore, the four z-scored domains were equally integrated into a broad global cognitive 
index (GCI). 
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Statistical analysis 
Statistical analyses were performed with SPSS Statistics 19.0 (IBM, Switzerland). Effect sizes were 
calculated in SPSS and with G*Power 3.1 (Faul et al, 2007). Frequency data were analyzed by means 
of Pearson’s chi-square test. Group differences in cognitive test scores at baseline and follow-up were 
analyzed by analyses of variance (ANOVA). For the longitudinal analysis, cocaine user groups and 
subgroups were analyzed using mixed design analyses of covariance (ANCOVA), omnibus tests 
(group*time) were followed by Sidak-corrected pairwise pre-post comparisons adjusted for test-retest 
effects. Because ADHD has previously been linked to both, cognitive performance in cocaine users 
(Vonmoos et al, 2013) and substance use in general (Wilson, 2007), mixed design analyses were 
corrected for ADHD as measured by the ADHD Self-Rating scale (Roesler et al, 2004). Given that we 
expected inevitable test-retest effects in all groups and because we aimed to estimate the change of the 
cocaine using groups relative to the control group, in which the general cognitive performance should 
be constant across one year, we corrected the user groups’ change scores by subtracting the mean 
change score of the control group. To relate cognitive change scores to varying cocaine use during the 
test interval, Pearson product-moment correlation analyses (two-tailed) were conducted in the cocaine 
user group. The confirmatory statistical comparisons were carried out on a significance level of p<.05 
(two-tailed). 
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Results 
Demographic characteristics and drug use  
Controls, increasers, and decreasers did not differ regarding demographic data and time interval 
between baseline and follow-up (Table 1, for details considering the not further analyzed group of 
stable cocaine users, see Table S1). However, as previously shown, both cocaine user groups 
displayed significantly higher BDI and ADHD-self-report sum scores than controls (Vonmoos et al, 
2013). Hair samples and cumulative doses revealed a clear dominance of cocaine compared with other 
illegal drugs, as intended by the inclusion and exclusion criteria. At baseline, increasers and 
decreasers displayed similar cocaine hair concentrations; however, at follow-up increasers showed an 
approximately 10-fold higher concentration of cocaine than decreasers. Whereas hair analyses for 
increasers showed a 3-fold increase between baseline and follow-up, decreasers displayed only a forth 
of the cocainetotal hair concentration after one year. In contrast to baseline, none of the self-reported 
cocaine use parameters correlated with hair cocaine concentrations in the follow-up (r=.02-.29, p=.89-
.08), highlighting the importance of objective drug use measures in longitudinal studies (Table S2).  
 
Test scores at baseline 
As previously demonstrated in the cross-sectional sample of this study (Vonmoos et al, 2013), 
ANOVAs showed significant group effects for the GCI, both memory domains, and the executive 
function but only a statistical trend for attention (Table 2, for details regarding single test parameters, 
see Table S3), indicating moderate to strong cognitive impairments in both cocaine user groups 
compared with controls (Cohen’s d=0.47–0.79). Increasers and decreasers did not substantially differ 
in the GCI (p=.99, d=0.08) and all four domains (p≥.94, d≤0.14) at baseline.  
 
Change between baseline and follow-up 
Because of strong test-retest effects, at the follow-up all groups displayed a better performance on the 
GCI, all domains, and the majority of single tests compared to baseline (Table 2). Of note, test-retest 
improvements in controls and decreasers were substantially stronger than in the increaser group. 
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An ADHD-corrected mixed ANCOVA for the two user groups revealed a significant group*time 
interaction effect on working memory (F1,35=4.85, p<.05, pη2=.12)(Figure 1). Furthermore, there was a 
non-significant trend for a group*time interaction in the GCI (F1,35=2.96, p=.09, pη2=.08)(for a GCI 
analysis including the group of stable cocaine users, see Figure S2). However, the effect sizes of the 
group*time interactions regarding declarative memory (F1,35=2.11, p=.16, pη2=.06), attention 
(F1,35=.73, p=.40, pη2=.02), and executive functions (F1,35=.15, p=.70, pη2=.004) were rather small. 
In subsequent pairwise Sidak pre-post comparisons adjusted for test-retest effects (Figure 1, Table 
S4), increasers showed a significant cognitive decline in working memory (p<.05, d=-0.52). 
Additional exploratory analysis revealed small effect sizes for a decline in increasers with regard to 
declarative memory (d=-0.16), attention (d=-0.04), and GCI (d=-0.21). By contrast, performance 
improvements of the decreasers were not significant but revealed small to moderate effect sizes in 
attention (d=0.22), working memory (d=0.21), declarative memory (d=0.30), and the GCI (d=0.33).  
Additionally, correlation analyses within a consolidated group of increasers and decreasers indicated 
a significant association between cumulative cocaine dose used during the test interval and change 
scores in attention (r=.34, p<.05) as well as a significant relation between changes in the hair 
parameter cocainetotal and change scores in the declarative memory (r=.39, p<.05)(for details see Table 
S5).  
As we have previously shown that age of onset was an important modulator of cognitive performance 
in cocaine users (Vonmoos et al, 2013), we further investigated whether age of onset was linked to the 
significantly different change in working memory of cocaine increasers and decreasers during the test 
interval. Whereas the increasers did not show any substantial correlation between age of onset and 
working memory change score (r=-.10, p=.68), there was a significant association in cocaine 
decreasers (r=.54, p<.05), indicating that early onset of cocaine use goes along with reduced recovery 
of working memory when cocaine use is considerably reduced (Figure 2).  
To analyse whether decreasers recover depending on their initial level of cocaine use, we correlated 
their cocaine use levels at baseline (hair concentration cocainetotal) with the cognitive change scores. 
However, we did not find a significant correlation in the GCI (r=-.10, p=.68, n=19) or any other 
domain (r=-.35-.18, p=.14-.47, n=19).  
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Test scores at follow-up 
In contrast to baseline, decreasers performed slightly, albeit non-significantly better than increasers 
on the GCI (d=0.37), all domains (d=0.14–0.42), and each single parameter (d=0.14–0.49)(Table 2). 
Accordingly, the domain differences between decreasers and controls were reduced to non-significant 
small to moderate effect sizes (d=0.24–0.59). Controls and increasers still differed significantly in the 
GCI (d=0.85), working memory (d=0.95), and declarative memory (d=0.78).  
 
Impact of ceased and strongly intensified cocaine use 
To investigate the impact of ceased or strongly intensified cocaine use, we split cocaine increaser 
(low/high; cut-off ∆t2-t1 cocainetotal=10 ng/mg), and decreaser subgroups (ceased use/ongoing use; cut-
off cocainetotal ceased use at follow-up <0.5 ng/mg)(for a detailed subgroup description, see Table S6). 
Given the lack of power in such a four-group comparison, the mixed ANCOVA (corrected for ADHD) 
displayed only non-significant group*time interactions regarding all domains, but with some 
interesting effect sizes: GCI (F3,33=1.70, p=.19, pη2=.13), attention (F3,33=2.09, p=.12, pη2=.16), 
working memory (F3,33=1.89, p=.15, pη2=.15), declarative memory (F3,33=1.69, p=.19, pη2=.13), and 
executive functions (F3,33=0.22, p=.88, pη2=.02). As we were specifically interested in whether long-
term cocaine abstinence has an effect on cognition, we interpreted Sidak pre-post comparisons in the 
group of ceasing cocaine users. Notably, users who completely stopped cocaine use for at least six 
months (negative hair toxicology) displayed a significantly improved GCI (p<.05, d=0.93), attention 
(p<.05, d=1.10), and declarative memory (p<.05, d=.65), resulting in follow-up test scores in the range 
of the control group (Figure 3).  
An ADHD-corrected mixed ANCOVA of the GCI including only cocaine increasers stratified 
according to positive (n=12) and negative cocaine urine toxicologies (n=7) at baseline and follow-up 
did not reveal a significant group*time interaction (F1,16=0.00, p=.99, pη2=.00), indicating that recent 
cocaine use likely did not explain the decline in test performance in increasers (Figure S3). Because 
only one cocaine decreaser featured a positive urine toxicology analysis at the follow-up, we did not 
analyze the group of decreasers further. 
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Discussion 
This longitudinal study is the first linking objectively quantified changes in cocaine use patterns 
during one year with the development of cognitive performance. Hair toxicology analyses allowed a 
precise drug use quantification to detect changes across the test interval and ensured the inclusion of 
participants with relatively little polytoxic drug use.  
This study yielded several major findings: First, increased cocaine use was associated with additional 
cognitive decline within one year, particularly in working memory, supporting the hypothesis that 
these cognitive impairments were partially cocaine-induced, as recent animal studies have implied 
(Gould et al, 2012; Liu et al, 2008; Olausson et al, 2007; Porter et al, 2011). This finding is also in 
line with previous cross-sectional studies showing that the extent, duration, and amount of cocaine use 
are related to the severity of cognitive dysfunction (Bolla et al, 1999; Colzato et al, 2007; Vonmoos et 
al, 2013). Second, decreased cocaine use within one year was linked to small but consistent cognitive 
improvements in all four domains confirming the assumption from previous cross-sectional and 
longitudinal studies that cognitive consequences from crack cocaine use might be partially reversible 
(De Oliveira et al, 2009; Di Sclafani et al, 2002). Users with moderate lifetime exposure who 
completely ceased their cocaine consumption seemed to recover entirely and attained a similar 
attention, memory, and global cognitive performance as controls in the follow-up. Because chronic 
cocaine administration to rhesus monkey produced neuroadaptations in dopamine systems 
(Letchworth et al, 2001; Nader et al, 2002), the reversibility of cognitive deficits after sustained 
abstinence suggests that neuroplastic adaptations might be restored if the repeated pharmacological 
stimulus is discontinued. Third, correlations between the cumulative cocaine dose used during the test 
interval and cognitive change scores, further support the hypothesis that cognitive decline might be 
drug-induced. Moreover, a substantial correlation between the age of cocaine use onset and change in 
working memory performance in decreasers indicates that early onset might be a risk factor for 
sustained cognitive impairment after chronic cocaine use.  
 
Users with escalating cocaine use displayed the largest cognitive decrements in working memory, 
confirming findings from our larger cross-sectional sample (Vonmoos et al, 2013) and from a meta-
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analysis (Jovanovski et al, 2005) that this domain is strongly affected in dependent cocaine users. The 
working memory domain was also improved if cocaine consumption was considerably decreased. 
These data suggest that either working memory is most susceptible to cocaine effects, as it has 
previously been associated with monoamine functioning (Robbins and Arnsten, 2009), or working 
memory tasks are the most reliable and sensitive test parameters. In fact, among controls, the test-
retest reliability of the declarative memory (r=.80), GCI (r=.78), and working memory (r=.77) was 
superior compared with executive function (r=.59) and attention (r=.55). 
Overall, the cognitive changes in our longitudinal study appear to be relatively small. However, at 
baseline, the increaser group already had a cumulative lifetime cocaine dose of 1.2kg – a level at 
which most cocaine users already display substantial cognitive impairments (Vonmoos et al, 2013). 
Given that the increasers reported an additional cumulative cocaine dose of 90g, used between 
baseline and follow-up, this amount might have been too small to exert additional and measurable 
cognitive decrements (in conjunction with possible ceiling effects).  
 
The putative reversibility of cognitive impairments in decreasers, particularly in working memory and 
declarative memory, confirms the results of two previous studies indicating memory improvements in 
cocaine users at six-months abstinence (De Oliveira et al, 2009; Di Sclafani et al, 2002). However, 
one study (De Oliveira et al, 2009) had a cross-sectional design, whereas the other (Di Sclafani et al, 
2002) postulated improvements but did not correct for test-retest effects. Another study (van Gorp et 
al, 1999) with cocaine users (n=37) found lasting detrimental effects in nonverbal declarative memory 
but small improvements in a verbal declarative memory test after 45 days of drug abstinence – a 
finding similar to the RAVLT results in our study. Moreover, a study with cocaine users (n=30) at one 
month of drug abstinence found no significant differences in learning and delayed recall compared 
with controls (Bolla et al, 1999). Because dependent cocaine users exhibited reduced activity in frontal 
regions (Volkow et al, 2009) crucial for cognitive functioning (Cabeza and Nyberg, 2000) and given 
that these reductions persisted at least three to four months after detoxification (Volkow et al, 1992), 
the abstinence duration in the last two studies mentioned here was supposedly too brief to reveal 
cognitive recovery effects.  
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The cognitive recovery process seemed to be particularly pronounced in users who ceased taking 
cocaine; at follow-up, all off these users had a GCI score within one SD of the control group. 
However, cocaine users who had been abstinent for at least six months also reported a relatively low 
cumulative lifetime dose of cocaine (0.7kg) compared with users with decreased but ongoing cocaine 
use (5.9kg). Because the abstinent user group did not significantly differ from the other cocaine use 
subgroups in terms of age, sex, verbal IQ, education, and ADHD, their putatively higher cognitive 
performance might be probably explained by this lower baseline use of cocaine. Nonetheless, it 
remains unclear if the subjects in this group became abstinent because of their higher overall 
functioning, or whether there is a “point of no return” none of these subjects attained (i.e., a 
cumulative cocaine dose beyond which no full recovery can be expected). Nevertheless, we propose 
that the reversibility of cognitive functions in cocaine users (1) takes some time (at least several 
months), (2) differs among cognitive domains, (3) depends on the residual level of cocaine use, and 
(4) is probably related to the amount of lifetime cumulative cocaine dose and age of onset. 
This study has some limitations. First, although the group assignment was based on objective hair 
toxicology covering the last six months, for the first six months of the time interval we could rely only 
on self-reports. Second, the importance of hair melanin pigment for the incorporation of cocaine into 
the hair structure has not been conclusively clarified (Mieczkowski and Newel, 2000). However, 
because there is no apparent melanin effect regarding cocaine (Mieczkowski and Kruger, 2007), and 
30 of 38 cocaine users in the present study had brownish hair, it is unlikely that the group assignment 
was affected by this potential constraint. We also used a within-subject design, and, thus, inter-
individual differences in hair color should play a minor role. Third, our executive function domain 
comprised only two parameters because we excluded the CANTAB IED from follow-up testing. 
Future longitudinal studies might therefore employ a more comprehensive neuropsychological test 
battery focusing on executive functioning. Fourth, although our sample consists of cocaine users with 
relatively little polytoxic drug use, it should be mentioned that at baseline, cocaine increasers 
displayed a small but significantly higher use of MDMA (0.04 vs. 0.01 tablets per week) and longer 
use of amphetamine (3.3 vs. 1.3 years) than decreasers. Furthermore, at follow-up cocaine increasers 
revealed a slightly higher use of MDMA and methylphenidate compared to baseline and featured an 
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additional rise in weekly alcohol use. Whereas the change in MDMA use was less than half a tablet 
per week, the difference in methylphenidate consumption was explained by a single individual. The 
rise in weekly alcohol use was based on an increased intake in three of 19 cocaine increasers. 
However, exclusion of the single methylphenidate user and the alcohol increasing subjects did not 
change the main results in separate analyses. Thus, although changes in other drugs should be 
considered as a contributing factor to our results, it seems reasonable that compared to the strong 
increase in cocaine use, the effect of changed use of other drugs is likely rather small. 
 
In conclusion, our findings suggest that cognitive performance co-varies with changing cocaine use 
within a one-year period. Whereas increased cocaine use was associated with further decrements of 
cognitive functioning (most pronounced in working memory), decreased cocaine use was linked to 
improved cognition, particularly in attention and the memory domains. Remarkably, cocaine users 
who completely ceased their consumption attained the same cognitive performance level as the 
controls. However, early age of cocaine use onset seem to hamper these recovery processes, at least in 
the working memory, which is a highly relevant finding for prevention and harm reduction 
interventions. While previous research has discussed the possibility of neuroenhancement in stimulant 
users by drugs (Sofuoglu et al, 2013), our findings suggest that drug abstinence might be the best way 
to recover cognitive performance in stimulant users as abstinence has obviously a more beneficial 
side-effect profile than any psychopharmacological intervention. Although it has been shown that 
stimulant treatment can improve cognitive performance in cocaine users at least acutely (Sofuoglu et 
al, 2013), the use of prescription stimulants to treat cognitive deficits in stimulant users might be 
questioned given that methylphenidate and amphetamines likely produce or even prolong 
neuroplasticity induced by cocaine or other illegal stimulants as they have similar mechanisms of 
action (Svetlov et al, 2007). However, the chronic effect or the discontinuation of pro-cognitive 
stimulant treatment on cognition of cocaine users has not been investigated so far. Finally, the general 
reversibility of cognitive deficits also indicates that drug-induced neuroadaptations can probably be 
remodulated by psychotherapeutical or pharmacological interventions, which might help to achieve 
and maintain abstinence.  
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Table 1. Demographic data and pattern of cocaine use. 
 Baseline (t1)  1-year follow-up (t2)m 
  
Controls 
(n=48) 
Cocaine  
Increaser 
(n=19) 
Cocaine  
Decreaser 
(n=19) 
F/χ²/T df, dferr p 
Effect 
size  
Controls 
(n=48) 
Cocaine  
Increaser 
(n=19) 
Cocaine  
Decreaser 
(n=19) 
F/χ²/T df, dferr p 
Effect 
size 
Age, y 30.3 (8.9) 31.5 (9.4) 31.4 (8.3) .20a 2,83 .82 pη2=.00         
Sex (f/m)  16/32 3/16 5/14 2.11b 2 .35 V=.16         
Verbal IQ (MWT-B)d 107.6 (10.0) 102.9 (9.7) 103.8 (7.1) 2.20a 2,83 .12 pη2=.05         
Education, y 10.8 (1.8) 10.4 (1.8) 10.0 (1.5) 1.30a 2,83 .28 pη2=.03         
ADHD-SR score (0-22) 7.7 (5.2) 13.5 (9.4)** 14.1 (6.8)** 8.83a 2,83 <.001 pη2=.18         
ADHD DSM IV (y/n)e 0/48 4/15 3/16 7.02b 2 .03 V=.28         
Weeks between t1 and t2 58.2 (10.1) 59.3 (12.1) 61.9 (14.5) .69a 2,83 .50 pη2=.02         
      
 
 
 
       
BDI score (0-63) 3.5 (3.3) 7.3 (8.0)* 8.7 (6.5)** 7.53a 2,83 <.001 pη2=.15         
BDI depression (y/n)g 0/48 1/18 1/18 2.59b 2 .27 V=.17         
                
Cocaine                
  Times per weekh - 1.6 (1.8) 1.0 (1.3) 1.17c 36 .25 d=.38  - 1.1 (0.8) 0.3 (0.3) 3.85c 36 <.001 d=1.32 
  Grams per weekh - 2.0 (2.5) 1.7 (2.3) .41c 36 .68 d=.12  - 1.6 (2.5) 0.4 (0.4) 2.18c 36 .04 d=.67 
  Years of use - 7.0 (5.5) 8.2 (5.4) .68c 36 .50 d=.22  - 8.9 (5.4) 9.7 (5.2) .45c 36 .65 d=.15 
  Max. dose (grams/day)k - 4.7 (4.4) 5.9 (6.4) .71c 36 .48 d=.22  - 3.7 (2.5) 3.1 (2.8) .63c 36 .53 d=.23 
  Cumulative dose (grams)k - 1182 (1635) 3698 (8585) 1.25c 36 .22 d=.41  - 91 (119) 49 (89) 1.25c 36 .22 d=.40 
  Last consumption (days) - 18.5 (25.1) 16.8 (14.6) .29c 36 .77 d=.08  - 7.0 (6.3) 81.4 (145.1) 2.23c 36 .03 d=.72 
  Cocaine craving (0-70)i - 19.8 (9.5) 17.7 (7.2) .79c 36 .44 d=.25  - 20.5 (10.8) 15.8 (6.2) 1.66c 36 .11 d=.53 
  Hair analysis (ng/mg)l                
    Cocainetotal - 10.3 (29.2) 14.9 (32.2) .46c 36 .65 d=.15  - 40.7 (76.1) 4.2 (8.2) 2.08c 36 .05 d=.67 
    Cocaine - 8.2 (23.3) 11.4 (23.9) .42c 36 .68 d=.14  - 31.7 (56.5) 3.1 (5.9) 2.19c 36 .03 d=.71 
    Benzoylecgonine  - 1.9 (5.5) 3.1 (7.6) .58c 36 .56 d=.18  - 8.3 (19.6) 1.0 (2.2) 1.62c 36 .11 d=.52 
    Cocaethylene - 1.0 (2.8) 0.9 (2.8) .11c 36 .91 d=.04  - 1.2 (2.1) 0.3 (1.0) 1.56c 36 .13 d=.55 
    Norcocainet - 0.2 (0.5) 0.4 (0.8) .83c 36 .41 d=.30  - 0.6 (1.4) 0.1 (0.1) 1.71c 36 .10 d=.50 
  Urine toxicology (n/p)k 48/0 14/5 16/3 .63b 1 .43 V=.13  48/0 7/12 18/1 14.15b 1 <.001 V=.61 
              
 
 
Alcoholn                
  Grams per weekh 119.9 (136.8) 169.4 (129.2) 155.3 (146.4) 1.07a 2,83 .35 pη2=.03  104.3 (88.6) 259.7 (244.5)*** 127.4 (141.4)° 7.71 a 2,83 <.001 pη2=.16 
  Years of use 13.3 (8.8) 13.7 (7.6) 12.0 (7.3) .23a 2,83 .79 pη2=.01  14.0 (8.7) 14.8 (7.5) 12.6 (7.9) .34a 2,83 .71 pη2=.01 
                 
Nicotinen                
  Smoking (y/n)f 37/11 14/5 14/5 .13b 2 .94 V=.04  40/8 15/4 13/6 1.83b 2 .40 V=.15 
  Cigarettes per dayh 8.7 (8.7) 12.8 (11.2) 9.5 (8.2) 1.38a 2,83 .26 pη2=.03  8.2 (8.7) 13.4 (12.0) 8.2 (7.8) 2.31a 2,83 .11 pη2=.05 
  Years of use 9.3 (8.3) 10.4 (8.9) 12.7 (10.3) .95a 2,83 .39 pη2=.02  10.5 (8.8) 12.5 (8.6) 12.6 (9.9) .56a 2,83 .57 pη2=.01 
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Cannabisn                
  Grams per weekh 0.6 (1.6) 3.3 (8.9) 1.2 (2.3) 2.38a 2,83 .10 pη2=.05  0.5 (1.6) 2.1 (4.6) 1.1 (2.7) 2.28a 2,83 .11 pη2=.05 
  Years of use 4.5 (4.9) 9.5 (8.5)* 10.1 (9.7)* 5.92a 2,83 .004 pη2=.12  4.6 (5.9) 10.5 (9.8)* 8.6 (9.7) 4.64a 2,83 .01 pη2=.10 
  Cumulative dose (grams) 980 (3985) 3199 (5899) 2606 (6359) 1.61a 2,83 .21 pη2=.04  53.4 (180) 217.8 (526.5) 84.7 (189.6) 2.15a 2,83 .12 pη2=.05 
  Last consumption (days)j 39.3 (1.6);n=22 10.0 (0.4);n=14 25.4 (1.1);n=12 2.19a 2,45 .12 pη2=.09  36.5 (1.5);n=22 9.7 (0.4);n=13 50.8 (2.1);n=10 1.20a 2,42 .31 pη2=.05 
  Urine toxicology (n/p)k 42/6 15/4 14/5 2.03b 2 .36 V=.15  42/6 7/12 15/4 18.61b 2 <.001 V=.47 
                   
Amphetaminen                
  Grams per weekh 0.0 (0.1) 0.1 (0.1)** 0.0 (0.1) 5.18a 2,83 .008 pη2=.11  0.0 (0.0) 0.1 (0.2)** 0.0 (0.1) 5.89a 2,83 .004 pη2=.12 
  Years of use 0.0 (0.0) 3.3 (4.0)*** 1.3 (3.1)° 13 .73a 2,83 <.001 pη2=.25  0.1 (0.5) 3.2 (4.9)** 2.7 (5.5)* 7.46a 2,83 .001 pη2=.15 
  Cumulative dose (grams) 0.0 (0.1) 56.0 (177.6)* 16.2 (35.9) 2.99a 2,83 .06 pη2=.07  0.0 (0.1) 4.4 (8.9)** 1.4 (3.5) 6.47a 2,83 .002 pη2=.13 
  Last consumption (days)j 121.6 (5.1);n=1 73.6 (3.1);n=10 90.9 (3.8);n=3 .29a 2,11 .75 pη2=.05  17.5 (0.7);n=1 35.7 (1.5);n=8 99.8 (4.2) ;n=4 1.48a 2,10 .27 pη2=.23 
  Hair analysis (ng/mg) 0.0 (0.0) 0.1 (0.2)* 0.0 (0.0) 4.35a 2,83 .02 pη2=.09  0.0 (0.0) 0.1 (0.2) 0.1 (0.2) 2.89a 2,83 .06 pη2=.07 
                 
MDMAn                
  Tablets per weekh 0.0 (0.0) 0.0 (0.1)*** 0.0 (0.0)° 7.42 a 2,83 .001 pη2=.15  0.0 (0.0) 0.4 (0.9)** 0.0 (0.0)° 5.54 a 2,83 .006 pη2=.12 
  Years of use 0.3 (1.0) 3.5 (4.5)*** 2.4 (4.6)* 8.42a 2,83 <.001 pη2=.17  0.2 (1.4) 3.8 (5.5)** 3.2 (5.6)* 7.78a 2,83 <.001 pη2=.16 
  Cumulative dose (tablets) 1.3 (4.0) 108.8 (249.7)** 18.7 (46.2) 5.71a 2,83 .005 pη2=.12  0.2 (0.8) 17.0 (49.3)* 2.8 (5.2) 3.67a 2,83 .03 pη2=.08 
  Last consumption (days)j 5.0 (0.2);n=1 89.9 (3.7);n=7 40.2 (1.7);n=4 1.63a 2,9 .25 pη2=.27  91.2 (3.8);n=3 41.6 (1.7);n=6 47.8 (2.0);n=5 1.11a 2,11 .36 pη2=.17 
  Hair analysis (ng/mg) 0.0 (0.0) 0.3 (0.7) 0.4 (1.5) 2.23a 2,83 .11 pη2=.05  0.0 (0.0) 0.5 (0.8)*** 0.1 (0.3) 7.87a 2,83 <.001 pη2=.16 
                 
GHBn                
  Cumulative dose (pipettes) 0.0 (0.0) 0.5 (0.7) 0.5 (1.7) 3.36a 2,83 .04 pη2=.07  0.0 (0.0) 0.0 (0.0) 0.0 (0.0) - - - - 
                 
Hallucinogensn                
  Cumulative dose (times) 0.9 (2.2) 27.9 (72.8)* 9.9 (22.9) 3.92a 2,83 .02 pη2=.09  0.0 (0.0) 1.1 (1.6)*** 0.6 (1.5) 8.57a 2,83 <.001 pη2=.17 
                 
Methlyphenidaten                
  Cumulative dose (tablets) 0.0 (0.0) 20.2 (60.4)* 0.5 (2.3) 3.76a 2,83 .03 pη2=.08  0.0 (0.1) 67.7 (239.5) 0.3 (0.6) 2.72a 2,83 .07 pη2=.06 
  Hair analysis (ng/mg) 0.0 (0.0) 0.0 (0.1) 0.0 (0.0) 1.80a 2,83 .17 pη2=.04  0.0 (0.0) 0.1 (0.2)* 0.0 (0.0) 3.62a 2,83 .03 pη2=.08 
 
Means and standard deviations. Significant p values are shown in bold.  
a ANOVA (all groups, with significant Sidak post-hoc test vs. control group: *p<.05; **p<.01; ***p<.001; vs. cocaine increaser: °p<.05). b χ²-test (all groups/cocaine users only) for frequency data. c Independent t-
test (cocaine users only). d Verbal IQ was assessed by the Mehrfachwahl Wortschatz Intelligenztest (Lehrl, 1999). e ADHD-SR, ADHD self rating scale (cut-off DSM-IV criteria)(Roesler et al, 2004). f Smoking 
habits were assessed by the Fagerstroem Test of Nicotine Dependence (Heatherton et al, 1991). g BDI, Beck Depression Inventory (cut-off ≥18)(Hautzinger et al, 1994). h Average use during the last 6 months. i 
Craving for cocaine was assessed by the Brief-CCQ (Sussner et al, 2006). j Last consumption is averaged only for persons who used the drug in the last 6 months. k Urine toxicology (neg/pos) are based on cut-off 
value for Cocaine = 150 ng/ml and for Tetrahydrocannabinol 50 ng/ml (Substance Abuse and Mental Health Services Administration, 2008). The χ²-test for cocaine includes only cocaine users, the χ²-test for 
cannabis includes controls and cocaine users.  l Hair samples were voluntary and data are missing for three controls. m Parameters at follow-up refer to the 1-year period between t1 and t2. n At baseline, average use 
during the last 6 months. Use frequency, duration of use, and cumulative doses are averaged within the total group. 
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Table 2. Domain scores at the baseline (t1) and the 1-year follow-up (t2). 
 
Means and standard deviations. Significant p values are shown in bold.  
a ANOVA (all groups, with significant Sidak post-hoc test vs. control group: *p<.05; **p<.01; ***p<.001).  
Global cognitive index and cognitive domain scores are z-transformed values. Z-score transformation is based on control group mean and variance at baseline. 
 Baseline (t1)  1-year follow-up (t2) 
  
Controls 
(n=48) 
Cocaine  
Increaser 
(n=19) 
Cocaine  
Decreaser 
(n=19) 
Fa  df, dferr p 
Part. 
Eta2   
Controls 
(n=48) 
Cocaine  
Increaser 
(n=19) 
Cocaine  
Decreaser 
(n=19) 
Fa df, dferr p 
Part. 
Eta2 
Global Cognitive Index 0.00 (0.54) -0.52 (0.77)* -0.46 (0.73)* 6.26 2,83 .003 .13   0.24 (0.58) -0.36 (0.84)** -0.07 (0.72) 5.85 2,83 .004 .12 
                     
Neurocognitive domains 
                   
  Attention 0.00 (0.78) -0.45 (0.85) -0.41 (0.87) 2.94 2,83 .06 .07   0.29 (0.84) -0.18 (0.91) 0.04 (0.83) 2.19 2,83 .12 .05 
  Working memory 0.00 (0.70) -0.46 (0.91) -0.47 (0.69) 4.09 2,83 .02 .09   0.24 (0.64) -0.44 (0.80)** -0.14 (0.69) 7.17 2,83 .001 .15 
  Declarative memory 0.00 (0.76) -0.60 (1.12) -0.44 (1.11) 3.42 2,83 .04 .08   0.20 (0.66) -0.53 (1.19)* -0.02 (1.21) 4.10 2,83 .02 .09 
  Executive functions 0.00 (0.70) -0.58 (1.11)* -0.52 (0.96) 4.36 2,83 .02 .10   0.25 (0.79) -0.31 (1.19) -0.18 (0.65) 3.46 2,83 .04 .08 
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Figure legends 
 
 
Figure 1: Development of cognitive functioning in cocaine increasers and decreasers within one year. Z-scores 
and SE for the cognitive domains (corrected for ADHD). Z-score transformation was based on control group mean and standard 
deviation at baseline. Follow-up values were adjusted for the test-retest effect. Change in cognitive test performance from the 
baseline (t1) to the one-year follow-up (t2): Sidak post-hoc tests (*p<.05). GCI: increaser p=.36, d=-0.21, decreaser p=.14, 
d=0.33. Attention: increaser p=.87, d=-0.04, decreaser p=.30, d=0.22. Working memory: increaser p<.05, d=-0.52, decreaser 
p=.34, d=0.21. Declarative memory: increaser p=.44, d=-0.16, decreaser p=.21, d=0.30. Executive functions: increaser p=.92, 
d=0.02, decreaser p=.52, d=0.14. 
 
Figure 2: Correlation of age of cocaine use onset and working memory change scores (∆t2-t1)  in decreasing 
cocaine users (n=19). Pearson product-moment correlation (two-tailed): r=.54, p<.05. Working memory change scores were 
adjusted for the test-retest effect. 
 
Figure 3: Cognitive functions in low/high cocaine increasers and decreasers with ongoing/ceased cocaine use 
within one year. Z-scores and SE for the cognitive domains (corrected for ADHD). Z-score transformation was based on 
control group mean and standard deviation at baseline. Follow-up values were adjusted for the test-retest effect. Change in 
cognitive test performance from the baseline (t1) to the one-year follow-up (t2): Sidak post-hoc tests (*p<.05). GCI: increaserlow 
p=.61, d=-0.14, increaserhigh p=.41, d=-0.30, decreaserongoing p=.82, d=0.06, decreaserceasing p<.05, d=0.93. Attention: increaserlow 
p=.41, d=0.29, increaserhigh p=.23, d=-0.46, decreaserongoing p=.74, d=-0.08, decreaserceasing p<.05, d=1.10. Working memory: 
increaserlow p<.05, d=-0.60, increaserhigh p=.52, d=-0.42, decreaserongoing p=.58, d=0.20, decreaserceasing p=.42, d=0.22. 
Declarative memory: increaserlow p=.90, d=-0.04, increaserhigh p=.30, d=-0.29, decreaserongoing p=.99, d=-0.01, decreaserceasing 
p<.50, d=0.65. Executive functions: increaserlow p=.70, d=-0.09, increaserhigh p=.54, d=0.46, decreaserongoing p=.63, d=0.12, 
decreaserceasing p=.68, d=0.17. 
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Methods S1. Recruitment and selection.  
The recruitment focused on the greater area of Zurich and lasted from January 2010 (start recruitment) until March 2013 (finish of 
the follow-up). Participants were recruited via advertisements in local newspapers, online media, drug prevention and treatment 
centers, psychiatric hospitals, and by word of mouth. Eight-hundred-and-four prospective participants underwent a standardized 
telephone interview, whereof 240 subjects were tested in the cross-sectional study. Six participants were not re-invited to 
participate in the follow-up study (refusal study participation, psychiatric disorders or first-grade family member with 
schizophrenia). The remaining 234 participants (138 cocaine users, 96 controls) were contacted and invited for a follow-up test 
session twelve months after baseline testing. One-hundred-and-two participants (59 cocaine users, 43 controls) were not available 
for the follow-up study due to different reasons (not answering, losing interest, time reasons, death). One-hundred-and-thirty-two 
participants (56%; 79 cocaine users, 53 controls) agreed to be re-tested and participated in the follow-up. Twenty-seven of these 
subjects (22 cocaine users, 5 controls) had to be excluded from the final analyses due to hair analyses revealing illegal drug use not 
allowed by our exclusion criteria (e.g., opioids or excessive MDMA intake) or due to starting use of psychotropic medication (e.g., 
antipsychotics or antidepressants).  
 
 
Methods S2. Construction of cognitive domain scores. 
Thirteen predefined main cognitive test parameters were z-transformed on the basis of means and standard deviations of the control 
group (n=48) at t1. If necessary, test scores were reversed so that high scores always indicated a better cognitive performance. 
These parameters were reduced to the four cognitive domains attention, working memory, declarative memory, and executive 
functions according to theoretical a priori considerations and in accordance with previous literature findings as cited below. 
Furthermore, the four z-scored domains were equally integrated into a broad global cognitive index (GCI). Apart from the non-
consideration of two CANTAB Intra/Extradimensional Set Shifting Task (IED) parameters, we used exactly the same approach as 
in the previously published cross-sectional study (Vonmoos et al, 2013). 
 
Attention 
To assess attention, we primarily focused on sustained attention by including the two RVP parameters discrimination performance 
A’ and total of hits (Jones et al, 1992). In order to diversify this domain, we further added the RAVLT parameter trial 1, a 
supraspan measure with a strong attentional component (Lezak et al, 2004). 
 
Working memory 
The SWM parameter total errors tested the capability to retain spatial information and to manipulate remembered items in the 
working memory (Morris et al, 1988). The LNST score measured verbal working memory by summing up the number of correct 
responses (Wechsler, 1997). The PAL first trial memory score measured visual working memory by counting the number of 
correctly located patterns after the first presentation (Sahakian et al, 1988). 
 
Declarative memory 
Three RAVLT parameters were included to assess the verbal declarative memory performance: ∑trials 1-5, delayed recall trial 7, 
and adjusted recognition performance p(A). Furthermore, the two PAL parameters (adjusted total of errors and adjusted total of 
trials) were used to capture visual declarative memory (Sahakian et al, 1988).  
 
Executive functions 
Because we excluded the CANTAB IED from the longitudinal analysis due to an evident ceiling effect at baseline (Vonmoos et al, 
2013), the executive functions were measured by only two parameters. First, the SWM strategy score assessed the applied heuristic 
strategies (Morris et al, 1988), a typical feature of the executive functions. Second, the RAVLT recall consistency score is a 
parameter typically impaired in patients with prefrontal lesions (Benedict et al, 2005; Jokeit et al, 1997) and related with measures 
of executive functions (Beebe et al, 2000). 
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Table S1. Demographic data and pattern of drug use for the cocaine user group with a stable use pattern. 
 
  Baseline (t1)   1-year follow-up (t2)h 
Age, y 27.0 (5.6)   
Sex (f/m)  8/11   
Verbal IQ (MWT-B)a 104.5 (9.1)   
Education, y 10.3 (1.6)   
ADHD-SR score (0-22) 14.4 (10.2)   
ADHD DSM IV (y/n)b 4/15   
Weeks between t1 and t2 64.8 (16.3)   
BDI score (0-63) 8.1 (6.2)   
BDI depression (y/n)d 2/17   
     
Cocaine    
  Times per weeke 0.6 (0.6)  0.3 (0.2) 
  Grams per weeke 0.7 (0.6)  0.2 (0.3) 
  Years of use 5.4 (5)  6.3 (5.6) 
  Max. dose (grams/day)k 3 (3.1)  1.7 (1.5) 
  Cumulative dose (grams)k 394.4 (563)  18.3 (25.4) 
  Last consumption (days) 42.2 (49.7)  58.2 (116.6) 
  Cocaine craving (0-70)f 18.4 (7.7)  15.1 (7.7) 
  Hair analysis, ng/mg    
    Cocainetotal 3.2 (9.9)  3.2 (9.4) 
    Cocaine 2.5 (7.6)  2.6 (7.9) 
    Benzoylecgonine  0.6 (1.9)  0.4 (1.2) 
    Cocaethylene 0.3 (0.8)  0.7 (2.1) 
    Benzoylecgonine  0.1 (0.3)  0.1 (0.3) 
  Urine toxicology (n/p)g 18/1  16/3 
    
Alcoholk    
  Grams per weeke 132.3 (86.4)  146.7 (95.1) 
  Years of use 9.9 (5.0)  11.1 (5.5) 
     
Nicotinek    
  Smoking (y/n)c 14/5  15/4 
  Cigarettes per daye 12.2 (8.3)  12.7 (8.9) 
  Years of use 9.2 (6.3)  9.5 (6.7) 
     
Cannabisk    
  Grams per weeke 1.2 (2.6)  0.9 (1.6) 
  Years of use 7.8 (5.9)  8.4 (6.2) 
  Cumulative dose (grams) 1932.7 (4309.1)  55.0 (94.7) 
  Last consumption (days)i 28.7 (41.1);n=15  18.7 (33.1);n=13 
  Urine toxicology (n/p)g 16/3  15/4 
       
Amphetaminek    
  Grams per weeke 0.0 (0.1)  0.0 (0.1) 
  Years of use 1.4 (3.0)  1.9 (3.5) 
  Cumulative dose (grams) 2.8 (5.8)  1.9 (6) 
  Last consumption (days)i 61.8 (59.6);n=7  65.9 (23.2);n=3 
  Hair analysis ng/mg 0.0 (0.0)  0.0 (0.0) 
 
MDMAk    
  Tablets per weeke 0.0 (0.0)  0.1 (0.1) 
  Years of use 2.1 (3.8)  2.6 (4.3) 
  Cumulative dose (tablets) 14.6 (39.9)  4.3 (7.1) 
  Last consumption (days)i 56.4 (43.4);n=6  69.7 (36.4);n=8 
  Hair analysis ng/mg 0.2 (0.5)  0.2 (0.4) 
     
GHBk    
  Cumulative dose (pipettes) 4.5 (17.8)  1.2 (5.2) 
     
Hallucinogensk    
  Cumulative dose (times) 6.3 (14.3)  0.4 (0.8) 
     
Methlyphenidatek    
  Cumulative dose (tablets) 41.3 (144.6)  1.5 (4.6) 
  Hair analysis ng/mg 0.0 (0.0)  0.0 (0.0) 
Pearson’s product-moment correlations in cocaine users (n=38). Significant correlations are marked: *p<.05; **p<.01. 
Means and standard deviations.  
a Verbal IQ was assessed by the Mehrfachwahl Wortschatz Intelligenztest (Lehrl, 1999).  
b
 ADHD-SR, ADHD self rating scale (cut-off DSM-IV criteria)(Roesler et al, 2004).  
c
 Smoking habits were assessed by the Fagerstroem Test of Nicotine Dependence (Heatherton et al, 1991).  
d
 BDI, Beck Depression Inventory (cut-off ≥18)(Hautzinger et al, 1994). 
e
 Average use during the last 6 months.  
f
 Craving for cocaine was assessed by the Brief-CCQ (Sussner et al, 2006).  
g
 Cut-off values for cocaine = 150 ng/ml and for tetrahydrocannabinol = 50 ng/ml (Substance Abuse and Mental Health Services Administration, 2008).  
h
 Parameters at follow-up refer to the 1-year period between t1 and t2. i
 Last consumption is averaged only for persons who used the drug in the last 6 months. 
k
 Use frequency, duration of use, and cumulative doses are averaged within the total group. 
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Table S2. Correlations between self reported cocaine use parameters and the hair toxicology parameter 
cocainetotal. 
 
  
Cocaine Users 
(n=38) 
Cocaine 
Increasers 
(n=19) 
Cocaine 
Decreasers 
(n=19) 
        
Cocaine self-report at baseline Cocainetotala Cocainetotal  Cocainetotal  
  Times per week .18 *.48 -.16 
  Grams per week -.04 .12 -.18 
  Years of use *.38 .39 .35 
  Max. dose (grams/day) *.39 -.06 **.67 
  Cumulative dose lifetime (grams) **.48 .22 **.62 
     
Cocaine self-report at 1-year follow-up Cocainetotala  Cocainetotal  Cocainetotal  
  Times per week .14 -.05 .03 
  Grams per week .08 -.04 .16 
  Years of use .07 .12 .28 
  Max. dose (grams/day) .29 .40 .06 
  Cumulative dose in the last year (grams) .02 -.06 -.01 
    
    
Pearson’s product-moment correlations in cocaine users (n=38). Significant correlations are marked: *p<.05; **p<.01. 
Cocaine parameters at 1-year follow-up refer to the period between t1 and t2. 
a
 Cocainetotal = Cocaine + Benzoylecgonine + Norcocaine.  
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Table S3. Cognitive test scores at the baseline (t1) and the 1-year follow-up (t2).
 
 
Means and standard deviations. Significant p values are shown in bold.  
a ANOVA (all groups, with significant Sidak post-hoc test vs. control group: *p<.05; **p<.01; ***p<.001).  
b In the RAVLT task, the value for one control subject is missing due to a technical failure. 
 
 Baseline (t1)  1-year follow-up (t2) 
  
Controls 
(n=48) 
Cocaine  
Increaser 
(n=19) 
Cocaine  
Decreaser 
(n=19) 
Fa  df, dferr p 
Part. 
Eta2   
Controls 
(n=48) 
Cocaine  
Increaser 
(n=19) 
Cocaine  
Decreaser 
(n=19) 
Fa df, dferr p 
Part. 
Eta2 
                
Attention 
                   
  RVP Discrimination perf. A' 0.92 (0.04) 0.90 (0.04) 0.90 (0.04) 1.92 2,83 .15 .04   0.93 (0.04) 0.91 (0.04) 0.92 (0.04) 2.00 2,83 .14 .05 
  RVP Total hits 18.35 (4.21) 16.26 (4.62) 16.79 (4.38) 1.95 2,83 .15 .04   19.98 (4.19) 17.79 (4.77) 18.63 (3.85) 2.02 2,83 .14 .05 
  RAVLT Supraspan trial 1b 9.38 (2.47) 8.47 (2.2) 8.26 (2.18) 1.99 2,82 .14 .05   9.66 (2.43) 8.68 (2.08) 9.37 (2.87) 1.06 2,82 .35 .03 
                     
Working memory 
                   
  LNST Score 15.54 (2.92) 14.00 (3.48) 14.00 (2.56) 2.84 2,83 .06 .06   15.69 (3.10) 13.74 (3.11) 14.32 (2.94) 3.27 2,83 .04 .07 
  SWM Total errors 20.31 (16.38) 27.11 (19.75) 26.95 (19.77) 1.49 2,83 .23 .03   13.52 (14.14) 25.53 (15.99)* 20.84 (15.64) 4.94 2,83 .009 .11 
  PAL First trial memory score 15.48 (3.87) 13.84 (4.26) 13.58 (2.43) 2.45 2,83 .09 .06   16.42 (3.08) 13.95 (3.63)* 15.63 (3.70) 3.71 2,83 .03 .08 
                     
Declarative memory 
                   
  RAVLT Learning perf. (∑trials 1-5)b 63.38 (6.53) 57.37 (9.66)* 57.84 (10.30)* 5.19 2,82 .008 .11   64.40 (6.64) 58.26 (10.55)* 62 (10.00) 3.63 2,82 .03 .08 
  RAVLT Adjusted recognition p(A)b 0.87 (0.11) 0.84 (0.19) 0.85 (0.14) .54 2,82 .59 .01   0.87 (0.11) 0.84 (0.16) 0.86 (0.18) .31 2,82 .73 .01 
  RAVLT  Delayed recall trial 7b 13.19 (2.00) 12.00 (3.04) 11.89 (2.92) 2.66 2,82 .08 .06   13.66 (1.77) 12.05 (3.66) 13.42 (2.39) 3.00 2,82 .06 .07 
  PAL Total errors adjusted 11.96 (13.76) 19.32 (15.73) 15.00 (12.11) 1.95 2,83 .15 .04   6.96 (6.69) 18.47 (16.17)** 11.74 (17.59) 6.17 2,83 .003 .13 
  PAL Total trials adjusted 8.71 (3.44) 10.74 (4.01) 9.63 (3.29) 2.31 2,83 .11 .05   7.88 (2.20) 10.37 (4.09)** 8.47 (3.61) 4.62 2,83 .01 .10 
                 
Executive functions 
                   
  SWM Strategy score 32.27 (6.13) 33.53 (6.28) 33.00 (5.45) .32 2,83 .72 .01   29.54 (6.03) 31.47 (6.81) 32.89 (4.41) 2.40 2,83 .10 .05 
  RAVLT Recall consistency (%) 93.05 (5.75) 87.54 (9.84)* 87.70 (8.61)* 5.52 2,82 .006 .12   93.43 (6.34) 88.76 (10.97) 91.61 (6.06) 2.61 2,82 .08 .06 
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Table S4. Test-retest effect adjusted and ADHD corrected cognitive change scores between baseline (t1) and 
one-year follow-up (t2).
 
 
Change scores (∆t2-t1) Cocaine Increasers (n=19) 
Cocaine Decreasers 
(n=19) 
   
Global Cognitive Index -0.09 (0.10) 0.15 (0.10) 
   
Neurocognitive domains 
  
  Attention -0.02 (0.15) 0.16 (0.15) 
  Working memory -0.22 (0.10) 0.10 (0.10) 
  Declarative memory -0.14 (0.18) 0.23 (0.18) 
  Executive functions 0.02 (0.17) 0.11 (0.17) 
    
Attention 
  
  RVP Discrimination perf. A' 0.00 (0.01) 0.00 (0.01) 
  RVP Total hits -0.10 (0.78) 0.22 (0.78) 
  RAVLT Supraspan trial 1 -0.10 (0.55) 0.86 (0.55) 
    
Working memory 
  
  LNST Score -0.40 (0.64) 0.16 (0.64) 
  SWM Total errors 5.14 (2.99) 0.76 (2.99) 
  PAL First trial memory score -0.83 (0.82) 1.12 (0.82) 
    
Declarative memory 
  
  RAVLT Learning perf. (∑trials 1-5) -0.24 (1.79) 3.25 (1.79) 
  RAVLT Adjusted recognition p(A) 0.01 (0.04) 0.02 (0.04) 
  RAVLT  Delayed recall trial 7 -0.44 (0.53) 1.08 (0.53) 
  PAL Total errors adjusted 4.25 (2.64) 1.65 (2.64) 
  PAL Total trials adjusted 0.49 (0.66) -0.35 (0.66) 
    
Executive functions 
  
  SWM Strategy score 0.66 (0.96) 2.64 (0.96) 
  RAVLT Recall consistency in % 0.73 (1.58) 3.64 (1.58) 
Mean change scores and standard errors (values corrected for ADHD). Change scores are adjusted for the test-retest effect. 
 
 
 7 
Table S5. Correlations between cognitive change scores and cocaine use parameters during the interval 
period. 
 
 
Cocaine use during the interval period 
(between baseline and 1-year follow-up) 
Change scores (∆t2-t1) Cumulative dose  (grams) 
Hair analysis 
Cocainetotal  
ng/mg 
     
Attention 
    
  RVP Discrimination perf. A' *.36   
  RVP Total hits *.34   
  RAVLT Supraspan trial 1     
      
Declarative memory 
    
  RAVLT Learning perf. (∑trials 1-5) .31   
  RAVLT Adjusted recognition p(A)   *-.39 
  RAVLT  Delayed recall trial 7 **.44 -.28 
  PAL Total errors adjusted     
  PAL Total trials adjusted     
      
Pearson’s product-moment correlations in cocaine users (n=35).  
Correlations with a p-level below 10% (2-tailed) are shown, while significant correlations are marked: *p<.05; **p<.01. 
Three cocaine users with more than 4 standard deviations difference in cumulative doses or cocainetotal were excluded. 
 8 
Table S6. Demographic data and hair analysis in cocaine user subgroups. 
 
  
Controls 
(n=48) 
Cocaine 
Increasers  
low, <10 ng/mg  
(n=11) 
Cocaine  
Increasers  
high, >10 ng/mg  
(n=8) 
Cocaine  
Decreasers 
ongoing use  
(n=11) 
Cocaine  
Decreasers  
no more use  
(n=8) 
F df,dferr p 
             
Global Cognitive Index ( ∆t2-t1)d 0.00 (0.38) -0.04 (0.48) -0.15 (0.42) 0.04 (0.51) 0.29 (0.34) 1.3a 4,81 .28 
            
Demographic data 
           
  Age, y 30.3 (8.9) 29.5 (8.5) 34.3 (10.4) 33.5 (9.3) 28.5 (6.0) .80a 4,81 .53 
  Sex (f/m)  16/32 3/8 0/8 3/8 2/6 3.84b 4 .43 
  Verbal IQ (MWT-B) 107.6 (10.0) 104.1 (12.1) 101.3 (5.5) 102.6 (8.5) 105.4 (4.7) 1.28a 4,81 .28 
  Education, y 10.8 (1.8) 10.7 (2.0) 10.0 (1.6) 10.3 (1.8) 9.6 (1.1) .99a 4,81 .42 
  Smoking (y/n) 37/11 9/2 5/3 8/3 6/2 1.08b 4 .90 
  BDI score (0-63) 3.5 (3.3) 7 (4.5) 7.8 (11.5) 8.5 (7.9) 9.0 (4.6) 3.72a 4,81 .008 
  ADHD-SR score (0-22) 7.7 (5.2) 12.5 (9.4) 14.9 (9.8) 13.3 (6.7) 15.1 (7.3)* 4.60a 4,81 .002 
  Weeks between t1 and t2 58.2 (10.1) 58.4 (11.0) 60.6 (14.2) 62.4 (13.9) 61.2 (16.4) .39a 4,81 .81 
            
Hair analysis cocainetotal ng/mg          
  t1 - 2.9 (3.0) 20.3 (44.6) 23.8 (40.7) 2.6 (2.6) 1.37c 3,34 .27 
  t2 - 5.8 (3.4)°° 88.7 (101.6) 7.2 (9.9)°° 0.1 (0.2)°° 6.90c 3,34 <.001 
  ∆t2-t1 - +2.9 (2.4)° +68.3 (83.8) -16.6 (34.5)°°° -2.5 (2. 6)° 6.82 c 3,34 .001 
                  
a
 ANOVA (all groups, with significant Sidak post-hoc test vs. control group:*p<.05).  
b
 χ² test (all groups) for frequency data. 
c
 ANOVA (only cocaine user groups, with significant Sidak post-hoc test vs. subgroup cocaine increaser high: °p<.05; °°p<.01; °°°p<.001).  
d
 GCI change scores are adjusted for the test-retest effect.   
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Figure S1. Hair concentration cocainetotal in three cocaine user groups at baseline (t1) and one-year follow-up 
(t2). 
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Hair concentration cocainetotal (ng/mg) in cocaine user groups. Means and standard deviation. A mixed design analysis (ANOVA) showed a significant  
group*test interaction effect (F2,54=5.70, p<.10). **indicates a significant pairwise Sidak pre-post comparison (p<.10).  
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Figure S2. Development of cognitive functioning in all three cocaine user groups within one year. 
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Development of cognitive functioning in cocaine user groups within one year. Z-scores and SE.  
Z-score transformation was based on control group mean and standard deviation at baseline. Values at follow-up were adjusted for the test-retest effect.  
A mixed design analysis (corrected for ADHD) showed a non-significant group*time interaction effect (F2,53=1.22, p=.30).  
Pairwise Sidak pre-post comparisons were non-significant for increasers (p=.41), decreasers (p=.18), and stable cocaine users (p=.89). 
 
 
As presented in Figure S1 (or more detailed in Table 1 and Table S1), the user group with stable cocaine use consists 
mainly of subjects with a comparatively low level of current cocaine use, whereas the increaser and decreaser groups 
consist of subjects with a substantially stronger former and/or current drug use. Consequently, GCI scores of the stable 
cocaine users are on a higher level than the GCI scores of the two other user groups.  
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Figure S3. Impact of cocaine urine toxicology status on global cognitive performance in cocaine increasers 
at baseline (t1) and 1-year follow-up (t2). 
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Development of cognitive functioning in cocaine user groups within one year. Z-scores and standard errors in groups stratified for  
urine toxicology (negative/positive) at baseline and follow-up in cocaine increasers (n=19).  
Z-score transformation was based on control group mean and standard deviation at baseline. Values at follow-up were adjusted for the test-retest effect.  
A mixed design analysis (corrected for ADHD) showed a non-significant group*time interaction effect (F3,14=0.75, p=.54).  
All pairwise Sidak pre-post comparisons were non-significant.  
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